N
BPMC

Natixis’s Blueprint Medicines BPMC Stock Holding History

Natixis’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,641
Closed -$339K – 1086
2025
Q2 		$339K Buy
+2,641
New +$274K ﹤0.01% 752
2025
Q1 		– Sell
-465
Closed -$40.6K – 993
2024
Q4 		$40.6K Sell
465
-89
-16% -$8.15K ﹤0.01% 902
2024
Q3 		$51.2K Sell
554
-29
-5% -$2.88K ﹤0.01% 783
2024
Q2 		$62.8K Sell
583
-185
-24% -$18.5K ﹤0.01% 774
2024
Q1 		$72.9K Buy
+768
New +$65.9K ﹤0.01% 801
2022
Q1 		– Sell
-2,286
Closed -$245K – 1170
2021
Q4 		$245K Sell
2,286
-149
-6% -$15.6K ﹤0.01% 1147
2021
Q3 		$250K Sell
2,435
-19
-0.8% -$1.77K ﹤0.01% 1121
2021
Q2 		$216K Buy
+2,454
New +$225K ﹤0.01% 812
2020
Q4 		– Sell
-329,844
Closed -$30.6M – 1041
2020
Q3 		$30.6M Buy
+329,844
New +$25.4M 0.23% 111

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Natixis's BPMC Position: Q3 2025 in Review

Natixis sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,641 shares — an estimated $339K sold.

Natixis first reported a position in BPMC in Q3 2020 and held it in 9 quarters. The position peaked at $30.6M in Q3 2020. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Natixis reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Natixis sold 2,641 Blueprint Medicines shares in Q3 2025, an estimated $339K.
  • Natixis first reported a position in Blueprint Medicines in Q3 2020 and held it in 9 quarters.
  • Natixis's Blueprint Medicines position peaked at $30.6M in Q3 2020.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Natixis's 13F filing for Q3 2025, filed 14 Nov 2025.